On March 30, 2026, Jayson Bedford of Raymond James elevated the rating for Boston Scientific Corporation (BSX) to ‘Outperform’, a move that underscores the firm’s confidence in the company’s growth trajectory and its potential to deliver substantial shareholder value. With the stock currently trading at $69.17 and an ambitious price target of $88, investors are keenly assessing what this upgrade means for both short- and long-term strategies.
Recent Price Action
In the wake of the rating change, BSX’s stock has experienced notable price fluctuations. Over the past week, it saw a decrease of 9.04%, reflecting a change of $6.25 amid an average trading volume of approximately 25 million shares—significantly above its three-month average of about 14.8 million. This uptick in trading activity suggests heightened investor interest, albeit set against the backdrop of broader market volatility. Currently, the stock sits well below its 52-week high of $99, which is $30.83 lower than its peak. However, it is notable that BSX has maintained a market capitalization of approximately $93.37 billion and a beta of 0.7, indicating relatively lower volatility compared to the overall market.
[chart type=’price’ value=’BSX’]
Short- and Long-Term Performance
When examining BSX’s stock performance over varying time frames, a mixed picture emerges. In the last 30 days, the stock is down by 3.47%, while it has seen a decline of 8.1% over the past 90 days. This trend continues into the past year, where the stock has recorded a loss of 7.1%. In terms of volatility, the weekly fluctuations have been notably higher at 3.19% compared to a monthly average of 1.99%, signaling increased uncertainty. Despite these challenges, BSX remains an attractive option for growth-oriented investors, particularly given the promising fundamentals and favorable analyst sentiments.
[chart type=’performance’ value=’BSX’]
Earnings and Financials
BSX recently reported earnings that outstripped expectations, with an actual earnings per share (EPS) of $0.75, surpassing the consensus estimate of $0.712 by a notable margin of approximately 5.34%. This performance mirrors the company’s EPS success from the previous quarter, where it also reported $0.75 against an estimate of $0.725—highlighting consistency and reliability in earnings quality. These results may bolster investor confidence, particularly as they point to a company able to maintain profitability even during challenging periods.
[chart type=’income-bar-chart’ value=’BSX’]
Analyst Consensus View
The consensus among analysts remains robust, with a striking total of 27 buy ratings and no holds or sells, culminating in a unanimous bullish outlook. The average price target stands at approximately $103.52, with a range extending from a low of $88 to a high of $124. The recent upgrade to an ‘Outperform’ rating from Raymond James signals not only confidence but also suggests that the stock is likely to perform better than the market in the coming quarters. This reinforces the belief that BSX is well-positioned for sustained growth.
[chart type=’analyst-ratings’ value=’BSX’]
Stocks Telegraph Grading Score
In terms of overall health and investment profile, BSX holds a Stocks Telegraph Grade (ST Score) of 41. While this score indicates room for improvement, it also reflects strong fundamentals and the company’s capacity for innovation within its sector. Such metrics are especially appealing to growth investors who prioritize both financial strength and market leadership.
[chart type=’st-cards’ value=’BSX’]
Conclusion
Boston Scientific Corporation emerges as a compelling opportunity for investors looking for long-term growth potential in the healthcare sector. With an ‘Outperform’ rating, strong financial performance, and a supportive consensus from analysts, BSX is well-equipped to navigate current market challenges. However, potential investors should also be mindful of the inherent risks, particularly the stock’s recent volatility and performance trends. Given these insights, BSX is worth monitoring for those seeking exposure to a leader in medical devices poised for future advancements.